AIDS最新文献

{"title":"Associations between HIV serostatus and coronary artery plaque volume progression.","authors":"Seamus P Whelton, Sabina A Haberlen, Long Zhang, Ryan Herrschaft, Mallory D Witt, Lisa P Jacobson, Joseph B Margolick, Jared W Magnani, Frank J Palella, Todd T Brown, Matthew Budoff, Wendy S Post","doi":"10.1097/QAD.0000000000004165","DOIUrl":"10.1097/QAD.0000000000004165","url":null,"abstract":"<p><strong>Objective: </strong>Men with HIV have more coronary atherosclerosis than men without HIV. We examined whether plaque progression differed based on HIV serostatus.</p><p><strong>Design: </strong>We examined plaque progression over a median of 4.5 years [interquartile range (IQR) 3.9-4.9] among 548 men with ( n  = 313) or without ( n  = 235) HIV from the Multicenter AIDS Cohort Study using coronary CT angiography.</p><p><strong>Methods: </strong>Change in coronary plaque volume was calculated for total, calcified, noncalcified, and low attenuation plaque and categorized by tertile. Multinomial logistic regression models estimated the association between HIV and coronary plaque progression.</p><p><strong>Results: </strong>The median age was 53 years and 30% were Black. Total plaque volume regressed among 2 and 20% remained without plaque, and 78% had progression with a median progression of 34 mm 3 (IQR 3-106). Compared to men without HIV, men with HIV had a statistically significant 1.99 higher odds of calcified plaque progression [95% confidence interval (CI) 1.16-3.44, P  = 0.01] and elevated odds for progression in total plaque [odds ratio (OR) 1.62, 95% CI: 0.94-2.77, P  = 0.08] and noncalcified plaque volume (OR 1.64, 95% CI 0.97-2.79, P  = 0.07], although the latter findings did not meet the cutpoint for statistical significance. The progression of low attenuation plaque did not significantly differ by HIV serostatus (OR 1.34, 95% CI: 0.88-2.05, P  = 0.18). HIV was significantly associated with the progression of total, calcified, and noncalcified plaque among non-Black participants, but not Black participants.</p><p><strong>Conclusion: </strong>These results suggest that men with HIV may have greater plaque progression, which may contribute to the observed higher incidence of coronary heart disease among men with HIV.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1413-1421"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Penile human papillomavirus prevalence in circumcised sexual minority men with and without HIV.","authors":"Nginache Nampota-Nkomba, Kareshma Mohanty, Ruxton Adebiyi, Charles Ekeh, Lisa M Schumaker, Kareemah T Suleiman, Laura Powell, Kara Lombardi, Nicholas P Ambulos, Elizabeth Shoyemi, Abdulwasiu B Tiamiyu, Michael G Homan, Mohammad M Sajadi, Søren M Bentzen, Kevin J Cullen, Trevor A Crowell, Rebecca G Nowak","doi":"10.1097/QAD.0000000000004209","DOIUrl":"10.1097/QAD.0000000000004209","url":null,"abstract":"<p><strong>Objective: </strong>Understanding the burden of penile human papillomavirus (HPV) among high-risk groups is essential to inform tailored prevention strategies to reduce HPV-related morbidity. We estimated the prevalence of penile HPV and its association with HIV among circumcised sexual minority men (SMM).</p><p><strong>Design: </strong>A cross-sectional study from a community-based cohort of SMM with and without HIV in Nigeria.</p><p><strong>Methods: </strong>Penile swabs were genotyped with a next-generation sequencing assay for any and high-risk HPV (HPV16/18/31/33/35/39/45/51/52/56/58/59/68). HIV status was ascertained using rapid diagnostic tests. Multivariable logistic regression models estimated the adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for the association between HIV and any and high-risk penile HPV.</p><p><strong>Results: </strong>Among 498 participants, median age was 24 (interquartile range: 22-28) years and 70.5% ( n  = 351) were living with HIV. The prevalence of any ( n  = 362) and high-risk ( n  = 239) penile HPV was 72.7% [95% confidence interval (95% CI): 68.6-76.4] and 48.0% (95% CI: 43.6-52.4), respectively. The most common high-risk HPV types were 16, 51, 45, and 18, while the most common low-risk types were 6 and 11. HIV was significantly associated with increased odds of any penile HPV (aOR 1.93, 95% CI: 1.20-3.12). Similar to any HPV, the association of HIV with high-risk penile HPV trended in the positive direction (aOR 1.45, 95% CI: 0.96-2.27), but it was not statistically significant.</p><p><strong>Conclusion: </strong>Penile HPV and HIV were highly prevalent among circumcised SMM in Nigeria. The most prevalent strains were vaccine-preventable, highlighting the need to prioritize HPV vaccination for boys as an additional strategy to prevent HPV-related morbidities.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1431-1440"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254017/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"As long-acting HIV prevention options gain momentum, the spotlight shifts to equitable access.","authors":"Iulia Filip","doi":"10.1097/QAD.0000000000004316","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004316","url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144740900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood pressure, weight change and incident hypertension after switching to dolutegravir in treatment-experienced people living with HIV.","authors":"Hans-Michael Steffen, Evelyn Viola, Agness Thawani, Layout G Kachere, Jacqueline Huwa, Claudia Wallrauch, Philipp Kasper, Florian Neuhann, Tom Heller, Volker Winkler, Ethel Rambiki, Melani R Mahanani","doi":"10.1097/QAD.0000000000004309","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004309","url":null,"abstract":"<p><strong>Objective: </strong>Dolutegravir (DTG) is recommended in WHO guidelines and has reportedly been associated with excess gain in body weight (BW).</p><p><strong>Design: </strong>In the prospective LighTen Cohort Study (ClinicalTrials.gov NCT02381275) we evaluated changes in BW and blood pressure (BP) of people living with HIV (PLHIV) who had initiated tenofovir (TDF)/lamivudine (3TC)/efavirenz (EFV; TLE). Follow-up continued after participants had been switched to TDF/3TC/DTG (TLD) in 2019.</p><p><strong>Methods: </strong>From the electronic medical record system, we retrieved data on BW and systolic BP of LighTen Cohort Study participants (age ≥18 years), who were still in care. We modelled BW and systolic BP over time utilizing interrupted time series (ITS) considering repeated measurements and adjusting for age and sex. Incident hypertension was defined as office BP ≥140/90 mmHg using ≥2 measurements on ≥2 consecutive visits.</p><p><strong>Results: </strong>Data of 543 PLHIV (317 females) were analysed. ITS showed an increase in BW of 1.24 kg/year on TLE with a minimal contribution (36.5 g/year) during DTG treatment, in contrast to the change in systolic BP: 0.33mmHg/year on TLE vs. 2.63mmHg/year on DTG. Incident hypertension in previously normotensive PLHIV was confirmed in 5.4% (while on TLE) versus 11.0% (while on TLD).</p><p><strong>Conclusions: </strong>Following the initial increase in BW on TLE, a larger increase in BP and a higher risk of incident hypertension was associated with switching antiretroviral therapy from TLE to TLD. Focussing on BP control while on DTG and timely initiation of antihypertensive drug therapy can help to reduce the burden of hypertension in PLHIV with their inherent increased cardiovascular risk.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No evidence of pitavastatin effect on muscle area or density among people with HIV.","authors":"Kristine M Erlandson, Triin Umbleja, Heather J Ribaudo, Michael T Lu, Jana Taron, Marissa R Diggs, Pamela S Douglas, Kathleen V Fitch, Carl J Fichtenbaum, Markella V Zanni, Judith A Aberg, Maria C Rodriguez-Barradas, Katharine Breaux, Rosalba Gomez Morones, Craig A Sponseller, Judith S Currier, Gerald S Bloomfield, Sarah M Chu, Alex B Lu, Carlos D Malvestutto, Steven K Grinspoon, Todd T Brown","doi":"10.1097/QAD.0000000000004306","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004306","url":null,"abstract":"<p><strong>Background: </strong>Skeletal muscle area (MA) and muscle density (MD) are key determinants of physical function and typically decline with increasing age. Statins have well-known musculoskeletal effects but whether statins impact MA or MD is not well established, especially in the setting of randomized treatment.</p><p><strong>Methods: </strong>REPRIEVE is a double-blind randomized trial evaluating the effect of pitavastatin for primary prevention of major adverse cardiovascular events in people with HIV (PWH). Thoracic paraspinal, pectoralis, and infraspinatus MA and MD were assessed among Mechanistic Substudy participants with CT at baseline and month 24.</p><p><strong>Results: </strong>Of 804 substudy participants, 510 remained on study treatment and had imaging at baseline and month 24. Median age was 51 years; 17% were natal female, 35% Black, and 27% Hispanic. There were no apparent changes in muscle measures from baseline to month 24 within the treatment groups. The estimated treatment group differences in baseline-adjusted month 24 outcomes were minimal (within 0.5 cm2/m for height-adjusted MA with 95% CI bounds within <1 cm2/m, and within 1 Hounsfield units (HU) for MD with 95% CI bounds within <3 HU; all p > 0.2). Findings were generally consistent in subgroup analyses.</p><p><strong>Conclusion: </strong>Pitavastatin was associated with no apparent change in muscle measures over 24 months, and with no evidence of detrimental effect among PWH.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association of immunosuppression and HIV control with Kaposi sarcoma among patients on antiretroviral therapy.","authors":"Anna E Coghill, Zachary Thompson, Laura Bamford, Greer Burkholder, Joseph Enron, Satish Gopal, Mari M Kitahata, Kenneth H Mayer, Richard Moore, George Yendewa, Brittney L Dickey, Elizabeth Yanik, Chad Achenbach","doi":"10.1097/QAD.0000000000004303","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004303","url":null,"abstract":"<p><strong>Objective: </strong>Access to antiretroviral therapy (ART) has resulted in a decline in Kaposi sarcoma (KS) incidence among people with HIV (PWH). However, KS is still occurring among PWH receiving ART, and it is important to understand the degree to which risk of KS is impacted by response to ART.</p><p><strong>Methods: </strong>We examined the changing epidemiology of KS among >20,000 PWH receiving HIV care between 1996 and 2016 in the Center for AIDS Research Network of Integrated Clinical Systems (CNICS). We evaluated the association of KS with CD4 count and HIV viral load at ART initiation, within 6-12 months, and during clinical follow-up.</p><p><strong>Results: </strong>A total of 344 PWH were diagnosed with KS. CD4 count <200 cells/uL at ART initiation was associated with a >6-fold increased KS risk. Likewise, an HIV viral load >50,000 copies/mL at ART initiation was associated with a >3-fold increased KS risk. For every 100 cells/uL increase in CD4 count or log-unit decrease in HIV viral load during the 12-18 months after ART initiation, we observed 11% and 7% lower KS risks, respectively. During clinical follow-up after ART initiation, every 10% increase in time with a CD4 count >350 cells/uL or an HIV viral load <500 copies/mL was associated with 24% and 26% lower KS risks, respectively. All results reported here were statistically significant at the p < 0.05 threshold.</p><p><strong>Conclusion: </strong>KS risk among PWH receiving HIV care was significantly impacted by not only CD4 count and viral load at ART initiation, but also long-term suppression of HIV after ART initiation.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glymphatic dysfunction in HIV: a resting-state fMRI biomarker linking cognitive impairment and immune suppression.","authors":"Ke Xue, YuXin Shi, Fengxiang Song, Danchao Cai, Jie Shen, Zecheng Yang, Fei Shan, Zhiyong Zhang, Yi Zhan","doi":"10.1097/QAD.0000000000004300","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004300","url":null,"abstract":"<p><strong>Objective: </strong>To investigate glymphatic dysfunction in people living with HIV (PLWH) and its associations with immunological status and cognitive function, utilizing the coupling strength of global blood-oxygen-level-dependent and cerebrospinal fluid (gBOLD-CSF).</p><p><strong>Design: </strong>Retrospective study of 75 PLWH and 52 non-HIV controls undergoing neuropsychological tests and resting-state functional magnetic resonance imaging (rs-fMRI).</p><p><strong>Methods: </strong>GBOLD-CSF coupling, Montreal Cognitive Assessment (MoCA) and seven cognitive domain scores were calculated. Group difference in gBOLD-CSF coupling strength was analyzed using a general linear model, adjusting for age, sex, and education. Partial correlation analyses were performed to examine the correlations of cognitive performance and immunological status with gBOLD-CSF coupling. Multivariate regression analysis was utilized to further evaluate the associations of gBOLD-CSF coupling with cognition.</p><p><strong>Results: </strong>PLWH exhibited significantly weaker gBOLD-CSF coupling than non-HIV controls (p = 0.018) and revealed impairments in attention/working memory, speed of information processing, and abstract/executive function (all p < 0.05). Reduced gBOLD-CSF coupling was associated with deficits in MoCA scores (r = -0.332, p = 0.004), verbal fluency (r = 0.245, p = 0.038), attention/working memory (r = 0.240, p = 0.042), speed of information processing (r = 0.245, p = 0.038), and abstract/executive function (r = 0.241, p = 0.042) in PLWH. Multivariate regression analysis showed gBOLD-CSF coupling was the only independent predictor for speed of information processing (β=0.410, p = 0.031) and MoCA scores (β=-0.399, p = 0.037). Weaker gBOLD-CSF coupling was correlated with lower nadir and current CD4 counts(r = -0.379, p = 0.019; r = -0.321, p = 0.049, respectively).</p><p><strong>Conclusion: </strong>Reduced gBOLD-CSF coupling in PLWH suggests glymphatic dysfunction and was associated with cognitive impairment and HIV-related immune suppression. It may serve as a non-invasive biomarker for monitoring cognitive disturbances and disease progression in HIV.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutralizing antibodies and restriction factors cooperatively exert selective pressure on the HIV-1 envelope glycoprotein.","authors":"Thomas Marceau, Julie Migraine, Alain Moreau, Youness Arrouche, Valérie Andriantsoanirina, Bernard Verrier, Fabrizio Mammano, Laurence Meyer, Martine Braibant","doi":"10.1097/QAD.0000000000004304","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004304","url":null,"abstract":"<p><strong>Objective: </strong>This study investigates the evolving susceptibility of HIV-1 envelope glycoproteins (Env) to restriction factors (IFITM3, SERINC5, MARCH8) as the infection progresses from the early to chronic phase, and explores the interplay between these factors and the humoral immune response, particularly neutralizing antibodies (NAbs).</p><p><strong>Design: </strong>We compared Env variants isolated from five subjects during the early and chronic phases of HIV infection. The study focused on evaluating the sensitivity of these variants to three restriction factors and their susceptibility to neutralization by autologous antibodies and human monoclonal antibodies (HuMobNAbs).</p><p><strong>Methods: </strong>Env-pseudotyped viruses were generated by co-transfecting HEK293T cells with plasmids encoding Env variants and restriction factors. Viral infectivity was measured using TZM-bl cells. Additionally, neutralization assays were performed with autologous serum samples and HuMobNAbs to assess how early and chronic variants responded to neutralizing antibodies in the presence or absence of restriction factors.</p><p><strong>Results: </strong>Env variants from the early phase were more sensitive to the antiviral effects of IFITM3, SERINC5, and MARCH8 compared to those from the chronic phase. Incorporating IFITM3 and SERINC5 into viral particles also increased the sensitivity of variants to autologous neutralizing antibodies and HuMobNAbs.</p><p><strong>Conclusions: </strong>HIV-1 Env evolution leads to resistance to both innate immune restriction factors and adaptive immune responses over time. However, incorporating IFITM3 and SERINC5 into virions enhances their sensitivity to neutralizing antibodies, suggesting a potential cooperative effect that could be exploited in therapeutic strategies. Further research is needed to investigate the mechanisms behind this enhancement and its potential impact on treatment approaches.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated high-sensitivity C-reactive protein and triglycerides in people with HIV treated with lipid-lowering therapy.","authors":"Anna Katrine Haslund Roed, Anne Marie Reimer Jensen, Andreas Dehlbæk Knudsen, Marco Gelpi, Thomas Benfield, Børge G Nordestgaard, Shoaib Afzal, Ole Kirk, Susanne Dam Nielsen","doi":"10.1097/QAD.0000000000004305","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004305","url":null,"abstract":"<p><strong>Objective: </strong>People with HIV (PWH) have an increased risk of cardiovascular disease, and many receive lipid-lowering therapy (LLT). However, it is unknown if PWH treated with LLT remain at a higher residual cardiovascular risk than persons from the general population. We investigated the risk of elevated biomarkers of inflammation and dyslipidemia associated with cardiovascular disease, among PWH and controls receiving LLT.</p><p><strong>Design: </strong>In this cross-sectional study, we included PWH from the Copenhagen Comorbidity in HIV infection (COCOMO) study and population controls from the Copenhagen General Population Study (CGPS), frequency matched 1:4 on age and sex. Among these, 142 PWH and 428 controls reported current treatment with LLT and were included in the analysis.</p><p><strong>Methods: </strong>We used multivariable logistic regression models to assess the association between HIV and biomarkers including high-sensitivity C-reactive protein (hs-CRP) ≥3.0 mg/L, low-density lipoprotein cholesterol (LDL-C) ≥2.6mmol/L, and triglycerides (TG) ≥2.26 mmol/L combined with high-density lipoprotein cholesterol (HDL-C) ≤1.03 mmol/L.</p><p><strong>Results: </strong>PWH had a higher risk of elevated hs-CRP (adjusted odds ratio (aOR) 1.97 [1.17-3.32], p  =  0.01) and of elevated TG (aOR 3.36 [1.94-5.81], p  <  0.01). No difference according to LDL-C risk was found. Our findings remained robust in sensitivity analyses adjusting for SCORE2 category, physical activity and exposure to thymidine analogues, and in subgroup analyses by antiretroviral therapy regimen, except for hs-CRP among PWH on protease inhibitor-based regimens.</p><p><strong>Conclusion: </strong>PWH receiving LLT had higher risk of elevated hs-CRP and TG compared to controls. This warrants increased attention and monitoring of treatment goals in PWH receiving LLT.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arterial stiffness in people with HIV: a cross-sectional, comparative study with echocardiographic outcomes in Tanzania.","authors":"Karl Reis, Ponsiano F Stephano, Salama Fadhil, Megan Willkens, Julie Karand, Elias Nyanza, Grace Ruselu, Ayubu Garubindi, Benson Issarow, Myung-Hee Lee, Cody Cichowitz, Robert N Peck","doi":"10.1097/QAD.0000000000004184","DOIUrl":"10.1097/QAD.0000000000004184","url":null,"abstract":"<p><strong>Objectives: </strong>Cardiovascular disease (CVD) is a growing cause of morbidity and mortality in people with HIV (PWH). Arterial stiffness may be an intermediary between HIV-infection and CVD, necessitating holistic assessment of arterial stiffness and correlation with cardiac outcomes.</p><p><strong>Design: </strong>We conducted a cross-sectional study of PWH and HIV-uninfected community controls using multimodal assessment of arterial stiffness and echocardiographic outcomes.</p><p><strong>Methods: </strong>We performed ankle-brachial index (ABI) and pulse wave velocity (PWV) to characterize arterial stiffness in a cohort of PWH and HIV-uninfected community controls in Tanzania. Regression analysis was used to determine differential risk factors for phenotypes of arterial stiffness and echocardiographic outcomes of these phenotypes.</p><p><strong>Results: </strong>We enrolled 848 participants; 398/848 PWH (46.9%) and 450/848 community controls (53.1%). In multivariable models, elevated ABI was associated with HIV infection [3.29 (1.51, 7.21), P  = 0.003] and male sex [2.33 (1.15, 4.71), P  = 0.019], whereas elevated PWV was associated with age [1.11 (1.06, 1.17), P  < 0.001], SBP [1.58 (1.24, 2.01), P  < 0.001], and DBP [2.03 (1.38-2.98) P  < 0.001]. ABI was independently associated with average E:e' [0.74 (0.18, 1.30), P  = 0.010]. PWV was independently associated with left-ventricular mass index (LVMI) [10.73 (2.69-18.76), P  = 0.009].</p><p><strong>Conclusion: </strong>Differential associations between HIV and multiple measures of arterial stiffness suggest that HIV is associated with peripheral but not central arterial stiffness. Arterial stiffness was correlated with cardiac hypertrophy and impaired cardiac filling, suggesting a mechanistic pathway for HIV-related CVD that includes peripheral arterial stiffness. We identified a subpopulation of young, male PWH at risk for early vascular aging.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1133-1140"},"PeriodicalIF":3.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143668677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}